Transenterix Inc (NASDAQ:TRXC)‘s stock had its “buy” rating reaffirmed by analysts at Stifel Nicolaus in a report released on Monday. They currently have a $4.00 price target on the stock, up from their prior price target of $3.75. Stifel Nicolaus’ target price indicates a potential upside of 68.78% from the company’s current price.
A number of other analysts have also recently commented on TRXC. Zacks Investment Research upgraded Transenterix from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Thursday, July 13th. Ladenburg Thalmann Financial Services set a $5.00 price objective on Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th.
Shares of Transenterix (TRXC) traded up 15.4051% on Monday, hitting $2.7351. 5,488,726 shares of the stock traded hands. Transenterix has a 12 month low of $0.45 and a 12 month high of $5.00. The firm’s 50 day moving average is $1.88 and its 200-day moving average is $1.02. The company’s market cap is $406.26 million.
COPYRIGHT VIOLATION WARNING: “Transenterix Inc (TRXC) Earns “Buy” Rating from Stifel Nicolaus” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2017/10/30/stifel-nicolaus-increases-transenterix-inc-trxc-price-target-to-4-00.html.
In related news, insider Todd Pope sold 600,000 shares of Transenterix stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total transaction of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares in the company, valued at approximately $1,702,529.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Large investors have recently modified their holdings of the business. LMR Partners LLP acquired a new stake in Transenterix in the 2nd quarter worth about $189,000. Global X Management Co. LLC boosted its stake in Transenterix by 238.3% in the 2nd quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock worth $235,000 after buying an additional 233,213 shares during the last quarter. Royal Bank of Canada boosted its stake in Transenterix by 17.1% in the 2nd quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock worth $298,000 after buying an additional 61,034 shares during the last quarter. UBS Oconnor LLC acquired a new stake in Transenterix in the 2nd quarter worth about $390,000. Finally, Goldman Sachs Group Inc. boosted its stake in Transenterix by 7,137.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock worth $854,000 after buying an additional 1,186,575 shares during the last quarter.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
What are top analysts saying about Transenterix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Transenterix Inc and related companies.